类风湿关节炎和心血管疾病的相互作用:见解和前景。

IF 2.1 Q2 MEDICINE, GENERAL & INTERNAL
SAGE Open Medicine Pub Date : 2025-07-23 eCollection Date: 2025-01-01 DOI:10.1177/20503121251330171
Anastasia V Poznyak, Nikolay A Orekhov, Alexey V Churov, Irina Alexandrovna Starodubtseva, Dmitry Felixovich Beloyartsev, Tatiana Ivanovna Kovyanova, Vasily N Sukhorukov, Alexander N Orekhov
{"title":"类风湿关节炎和心血管疾病的相互作用:见解和前景。","authors":"Anastasia V Poznyak, Nikolay A Orekhov, Alexey V Churov, Irina Alexandrovna Starodubtseva, Dmitry Felixovich Beloyartsev, Tatiana Ivanovna Kovyanova, Vasily N Sukhorukov, Alexander N Orekhov","doi":"10.1177/20503121251330171","DOIUrl":null,"url":null,"abstract":"<p><p>Rheumatoid arthritis significantly increases the risk of cardiovascular disease due to chronic inflammation. This review's purpose is to critically analyze the intricate relationship between rheumatoid arthritis and cardiovascular disease, highlighting the mechanisms by which systemic inflammation contributes to cardiovascular risk and the effectiveness of current treatment strategies. We systematically evaluate existing literature on conventional cardiovascular risk factors in rheumatoid arthritis patients, as well as inflammation-specific markers that influence cardiovascular outcomes. Our conclusions indicate that while several treatment modalities, including methotrexate and other disease-modifying agents, may mitigate cardiovascular risk, there is a prevalent underestimation of true risk by standard cardiovascular disease assessment protocols. This review provides unique contributions by emphasizing the importance of integrating novel risk factors into assessment protocols and advocating for personalized management strategies that cater to the specific needs of rheumatoid arthritis patients. By synthesizing these elements, we aim to enhance understanding and guide clinicians in improving outcomes for rheumatoid arthritis patients at heightened risk of cardiovascular complications.</p>","PeriodicalId":21398,"journal":{"name":"SAGE Open Medicine","volume":"13 ","pages":"20503121251330171"},"PeriodicalIF":2.1000,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12290359/pdf/","citationCount":"0","resultStr":"{\"title\":\"Interplay of rheumatoid arthritis and cardiovascular disease: Insights and prospects.\",\"authors\":\"Anastasia V Poznyak, Nikolay A Orekhov, Alexey V Churov, Irina Alexandrovna Starodubtseva, Dmitry Felixovich Beloyartsev, Tatiana Ivanovna Kovyanova, Vasily N Sukhorukov, Alexander N Orekhov\",\"doi\":\"10.1177/20503121251330171\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Rheumatoid arthritis significantly increases the risk of cardiovascular disease due to chronic inflammation. This review's purpose is to critically analyze the intricate relationship between rheumatoid arthritis and cardiovascular disease, highlighting the mechanisms by which systemic inflammation contributes to cardiovascular risk and the effectiveness of current treatment strategies. We systematically evaluate existing literature on conventional cardiovascular risk factors in rheumatoid arthritis patients, as well as inflammation-specific markers that influence cardiovascular outcomes. Our conclusions indicate that while several treatment modalities, including methotrexate and other disease-modifying agents, may mitigate cardiovascular risk, there is a prevalent underestimation of true risk by standard cardiovascular disease assessment protocols. This review provides unique contributions by emphasizing the importance of integrating novel risk factors into assessment protocols and advocating for personalized management strategies that cater to the specific needs of rheumatoid arthritis patients. By synthesizing these elements, we aim to enhance understanding and guide clinicians in improving outcomes for rheumatoid arthritis patients at heightened risk of cardiovascular complications.</p>\",\"PeriodicalId\":21398,\"journal\":{\"name\":\"SAGE Open Medicine\",\"volume\":\"13 \",\"pages\":\"20503121251330171\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-07-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12290359/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"SAGE Open Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/20503121251330171\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"SAGE Open Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20503121251330171","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

类风湿性关节炎会显著增加慢性炎症引起的心血管疾病的风险。本综述的目的是批判性地分析类风湿关节炎和心血管疾病之间的复杂关系,强调全身性炎症导致心血管风险的机制和当前治疗策略的有效性。我们系统地评估了现有文献中关于类风湿关节炎患者的常规心血管危险因素,以及影响心血管预后的炎症特异性标志物。我们的结论表明,虽然包括甲氨蝶呤和其他疾病调节剂在内的几种治疗方式可以降低心血管风险,但标准心血管疾病评估方案普遍低估了真实风险。这篇综述强调了将新的风险因素纳入评估方案的重要性,并倡导个性化的管理策略,以满足类风湿关节炎患者的特定需求,从而提供了独特的贡献。通过合成这些元素,我们的目标是加强理解和指导临床医生改善心血管并发症高风险的类风湿关节炎患者的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Interplay of rheumatoid arthritis and cardiovascular disease: Insights and prospects.

Interplay of rheumatoid arthritis and cardiovascular disease: Insights and prospects.

Interplay of rheumatoid arthritis and cardiovascular disease: Insights and prospects.

Interplay of rheumatoid arthritis and cardiovascular disease: Insights and prospects.

Rheumatoid arthritis significantly increases the risk of cardiovascular disease due to chronic inflammation. This review's purpose is to critically analyze the intricate relationship between rheumatoid arthritis and cardiovascular disease, highlighting the mechanisms by which systemic inflammation contributes to cardiovascular risk and the effectiveness of current treatment strategies. We systematically evaluate existing literature on conventional cardiovascular risk factors in rheumatoid arthritis patients, as well as inflammation-specific markers that influence cardiovascular outcomes. Our conclusions indicate that while several treatment modalities, including methotrexate and other disease-modifying agents, may mitigate cardiovascular risk, there is a prevalent underestimation of true risk by standard cardiovascular disease assessment protocols. This review provides unique contributions by emphasizing the importance of integrating novel risk factors into assessment protocols and advocating for personalized management strategies that cater to the specific needs of rheumatoid arthritis patients. By synthesizing these elements, we aim to enhance understanding and guide clinicians in improving outcomes for rheumatoid arthritis patients at heightened risk of cardiovascular complications.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
SAGE Open Medicine
SAGE Open Medicine MEDICINE, GENERAL & INTERNAL-
CiteScore
3.50
自引率
4.30%
发文量
289
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信